Dermira Announces Closing of Follow-on Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

MENLO PARK, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has closed its previously announced follow-on public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock, at a price to the public of $21.50 per share, all of which were sold by Dermira. Dermira estimates net proceeds from the offering to be approximately $104.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Leerink Partners LLC, Cowen and Company and Guggenheim Securities acted as joint book-running managers for the offering. Needham & Company acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 5, 2015. This offering was made solely by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at [email protected] or by telephone at 1-800-808-7525, ext. 6142; Cowen and Company, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-631-274-2806; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 1-212-518-9658 or by email to [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Dermira Contact
         Andrew Guggenhime
         Chief Operating Officer and Chief Financial Officer
         (650) 421-7200
         [email protected]

         Investor Contact
         Westwicke Partners
         Robert H. Uhl
         Managing Director
         (858) 356-5932
         [email protected]

You May Also Be Interested In

• Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
• Marex Group (MRX) Prices 15.38M Share IPO at $19/sh
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results